Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Bylvay
Pharma
Ipsen touts early launch results for liver disease drug Iqirvo
Ipsen’s Iqirvo is off to a solid launch as it battles with two other drugs to treat patients with the rare liver disease primary biliary cholangitis.
Kevin Dunleavy
Apr 17, 2025 8:47am
Mirum gets 2nd indication for blockbuster hopeful Livmarli
Mar 13, 2024 6:20pm
Mirum ponies up $445M for 2 Travere liver disease drugs
Jul 18, 2023 8:00am
After Albireo buyout, Ipsen's Bylvay picks up new use
Jun 13, 2023 2:02pm
Ipsen pays $952M to acquire Albireo and liver disease med Bylvay
Jan 9, 2023 10:05am
Mirum gets a leg up on Albireo in pediatric liver disease
Oct 24, 2022 3:11pm
